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Drago Iki} – portrait of a renowned Croatian
vaccinologist
Vision, mission, strategy and goals
Drago Iki} spent most of his career studying principles of vaccine
production, safety and effectiveness with an eye toward biological
standardization and quality assurance.
Key principles of his efforts were to:
• Develop new and improved vaccines and enhance vaccine safety
by building quality into the product in the first place.
• Increase national and then global prevention of death and disease
through safe and effective vaccination.
• Institute training on the job and self-improvement.
• Institute international and national education program.
• The need to know more about everything in the system
Drago Iki} was born on July 2, 1917. In 1936 he attended the School of
Medicine, University of Zagreb, earning an M.D. diploma in 1942, a
M.Sc. degree (Hygiene) in 1952, a M.Sc. degree (Bacteriology) in 1954,
and a Ph.D. degree in Immunology in 1958. His management skills and
performance were proven through numerous posts. Between 1952 and
1956, he chaired the Department for Control and Research of Vaccines at
the Central Institute of Hygiene in Zagreb, he ran the Institute for
Control and Research of Vaccines in 1956 and from 1958–1961, and
directed the Serovaccinal Institute in Zagreb from 1956–1958.
In 1961 Drago Iki} founded Institute of Immunology Zagreb. The
Institute of Immunology continued, like its predecessor Serovaccinal
Institute, with the research, development and production of immuno-
logical drugs and medicines derived from animal and human blood.
Drago Iki}’s vision was that the Institute of Immunology should be a
science-based organization that produces and regulates biological pro-
ducts, by helping stakeholders within the public health system in
fighting infectious diseases (preventive medicine), in treating diseases
with immunological drugs and medicines, and in increasing awareness
of the importance of continuous quality improvements. In order to
respond to these challenges in the best possible way, experts from the
Institute of Immunology, under the leadership of Drago Iki}, have
developed their competences by learning from the best European and
global examples of good practice and their own experience in quality
assurance procedures. Drago Iki} has initiated and actively participated
in a wide range of activities aimed at changes and reforms in the field of
quality assurance in public health, research (natural sciences, biomedi-
cine and biotechnology) and in higher education.
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Though Drago Iki} officially retired in 1982, he never
stopped working and continued to be industrious. As
Fellow of the Croatian Academy of Sciences and Arts
(former Yugoslav Academy of Sciences and Arts) from
1977, he founded in 1983 as part of the Department of
Medical Sciences, the Institute (nowadays Cabinet) for
Research and Standardization of Immunological Sub-
stances and become its titular director. His research focu-
ses on immunologically active substances in viral pre-
cancerous, cancerous, and other diseases. He continues
to cooperate with other scientific institutions at home
and abroad. An important part of his recent research was
the application of various interferons in head and neck
tumors and melanoma, as well as in precancerous and
cancerous conditions of the cervix uteri.
Drago Iki} is the author of over 225 scientific papers
and reviews, editor of many books and proceedings (list-
ed on his personal page at http://info.hazu.hr/regu-
lar_members). Headed by Drago Iki}, the Institute of
Immunology has organized eighteen international meet-
ings (mainly cosponsored by the Academy of Sciences
and Arts) resulting in 14 published proceedings in Eng-
lish. The meetings and published material cover the
following fields of interests: biological standardization
(1957), immunology (1959), microbiological standardi-
zation (1960), characterization and use of human di-
ploid cells (1963, 1970), biological standardization of cell
cultures (1964), oncogenicity of viral vaccines (1968),
small pox eradication (1969), acute respiratory diseases
(1969), influenza vaccine (live) (1971), bacterial vaccines
(1971, 1977), combined vaccines (1972), field trials of
vaccines (1973), production, standardization and clini-
cal use of interferons (1975, 1977, 1979), effectiveness
and stability of vaccines against measles, poliomyelitis
and pertussis (1976).
Drago Iki}’s remarkable contributions to the field of
microbiology and vaccinology in Croatia were repeatedly
awarded. Among his many accolades he received the
»Ru|er Bo{kovi}« award in 1972, a Life Achievement
award in 1980 from the Republic of Croatia, and Order of
Danica Hrvatska with the face of Ru|er Bo{kovi} in 2012
(Figure 1). However, despite his numerous awards and
prestigious accomplishments, Drago Iki} continues as
an extremely humble and down-to-earth man.
BACTERIAL VACCINES
Drago Iki}’s research created a new scientific para-
digm for development of live, attenuated virus vaccines.
But, in the mid 1940s, due to epidemic outbreaks of
diphtheria and typhoid fever, he began research on bac-
terial vaccines. At the brink of the 20th century, live
vaccines were being used worldwide for smallpox and
rabies, heat-killed vaccines for cholera, typhoid, and pla-
gue, and antitoxins for diphtheria and tetanus. Drago
Iki} found the prospect of being able to apply these
discoveries to prevent and treat these dangerous diseases
very exciting. Between 1946 and 1952 he completed his
training in bacteriology and hygiene in well-known Euro-
pean laboratories (Paris, Zurich, and Geneva) and studied
principles of vaccinology in London and Copenhagen.
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Figure 1. On July 28, 2012, the President of the Republic of Croatia, Ivo Josipovi}, presented awards to deserving persons. Drago Iki} (second on the left) was
awarded the Order of Danica Hrvatska with the face of Ru|er Bo{kovi} for outstanding contribution to science (http://www.predsjednik.hr/lipanj96).
After World War II the need arose for organized, well
planned and controlled field trials on bacterial vaccines
and in 1950s he joined the Yugoslav Typhoid Commis-
sion. In 1953, the Yugoslav Typhoid Commission organiz-
ed the first strictly controlled field trial of two types of
anti-typhoid vaccine in an attempt to determine the re-
lative and absolute effectiveness of each. The preliminary
report (1) published in 1957 has given the basic infor-
mation on the conditions of the trial, in which 35 508 per-
sons completed the course of two injections. The members
of the Commission were: Branko Cvjetanovic (School of
Public Health, Medical Faculty, University of Zagreb);
Hinko Emili (Chairman) (Central Institute of Hygiene,
Zagreb); Drago Iki} (Central Institute of Hygiene, Za-
greb); Ante Merd`o (General Hospital, Department for
Infective Diseases, Osijek); Fran Mihaljevi} (Fever Hospi-
tal and Department of Infectious Diseases of the Medical
Faculty, University of Zagreb); A. Nevidal (Institute of
Hygiene, Osijek); J. Rücker (Central Institute of Hygiene,
Zagreb) and Pavao Toma{i} (Central Institute of Hy-
giene, Zagreb). Drago Iki} supervised laboratory studies
and the protective value of heat-killed phenol-preserved
typhoid vaccine was confirmed (Figure 2).
Late in the 1950’s; Drago Iki} felt that the interest in
bacterial vaccines slackened and many have been attract-
ed by the development of virus vaccines. At the sympo-
sium on bacterial vaccines held at the Institute of Im-
munology in 1971 he proposed »a renaissance of bacterial
vaccines«. Further improvement of bacterial vaccines in
his view should have followed two trends: the develop-
ment of live, i.e. oral vaccine and the separation and
concentration of the active substance from the germs that
have been used for pneumococcal and meningococcal
vaccines and vaccines against H.influenzae infections.
Drago Iki} believed that oral vaccine is convenient for
mass prophylaxis of all diseases because of simple mode
of administration, the imitation of natural infection, and
the exploitation of local defence mechanisms, provided
that the protection offered by it is reasonable and the
vaccine harmless (2). His belief differed from the existing
dogma that vaccines made from killed or inactivated
microorganisms are safer than attenuated vaccines, which
are made from weakened, but live, microorganisms. Also,
there is a small chance that an attenuated vaccine might
cause the disease it is designed to prevent. Although first
attenuated vaccine was developed in 1885 when Pasteur
developed a vaccine against rabies based on live attenuat-
ed virus, the development of the first heat-killed vaccine
against cholera by Theobald Smith and Daniel Elmer
Salmon (3) a year latter was a major step in vaccine
development. The original work on heat-killed vaccines
proved to be highly valuable and over the next 20 years
led to the development of killed vaccines for several
human infectious diseases–typhoid, cholera, and plague.
It was not until 1927 that the following live vaccine was
developed: the bacille Calmette-Guérin (BCG vaccine)
against tuberculosis. Then after World War II the ability
to make cell cultures, i.e. the ability to grow cells from
higher organisms in the laboratory, made it easier to
develop new vaccines and the number of pathogens (mostly
viruses) for which vaccines could be made almost doubl-
ed. Despite his confidence that the development of new
and better bacterial vaccines is epidemiologically ever
more justified, Drago Iki} has slowly changed the focus
of his interest.
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Figure 2. Drago Iki} (second on the right) speaking at working meeting of experts on bacterial vaccines and standards at Andrija [tampar School of
Public Health, Medical School of the University of Zagreb in 1959.
VIRAL VACCINES
Vaccine research flourished because of new techni-
ques for growing viruses in tissue culture. Late in 1950’s
Hayflick and Moorhead (Wistar Institute, USA) began
their work on human fetal fibroblasts (4). It soon became
evident that such cultures were susceptible to human
viruses, were diploid and had a finite life time. The finite
lifetime of cultured, normal human and animal cells is a
reflection of the maximum capability of that cell lineage
to replicate. They can be frozen and stored in liquid
nitrogen at an early passage level, recover from frozen
ampoules years later and induced to divide again. One
such strain called WI-38 was the most widely used and
highly characterized normal human cell population in
the world. In September 1966, J.P. Jacobs (Medical Re-
search Council Laboratories, London) developed, stock-
ed and characterized another human diploid cell strain,
also derived from fetal lung tissue, MRC-5 for vaccine
manufacture. From the very beginning Drago Iki} was
deeply involved in the research and development of hu-
man diploid cell strains. At a meeting held in 1963 in
Opatija (proceeding was edited under direction of the
Institute of Immunology Zagreb), Drago Iki} and colla-
borators had nine presentations on poliovaccine and mea-
sles vaccine produced on human diploid cells (5). The
most prominent scientists in the field attended the meet-
ing (L. Hayflick, H. Eagle, J.P. Jacobs, H. Koprowski, P.S.
Moorhead, F. Perkins) and Drago Iki} established the
opportunity for continuous international collaboration.
Later, at the meeting held in October 1968 in Zagreb (6),
three problems were considered regarding the propaga-
tion of human diploid cells for use in preparing viral
vaccines for man: virally transformed cells, the presence of
oncogenic viruses and the presence of contaminating no-
noncogenic viruses or other organisms such as mycoplas-
mas. In considering these problems, general principles for
selection of a diploid cell substrate for viral vaccines were
suggested and published in Science – and Drago Iki} had
his place among distinguished experts (7).
Since the development in 1961 of a human diploid
cell strain (HDCS) culture system for isolating viruses,
HDCS-derived human vaccines have been licensed world-
wide for polio IPV and OPV (multiple strains); rabies
(Pitman-Moore L503 3M strain); rubella (RA27/3 strain);
measles (Edmonston-Zagreb strain); varicella-zoster (Oka
strain); mumps (Rubini strain) and hepatitis A (HM-
-175, CR-326-F, and GBM strains). Many of these widely
used vaccines now have at least a 30-year record of safety
after extensive, ongoing pharmacovigilance.
The first candidate poliovaccine, based on one sero-
type of a live but attenuated (weakened) virus, was de-
veloped by the virologist Hilary Koprowski. Koprowski’s
prototype vaccine was given to an eight-year-old boy on
February 27, 1950. Koprowski continued to work on the
vaccine throughout the 1950s, leading to large-scale trials
in the then Belgian Congo, Croatia and in Poland against
serotypes PV1 and PV3 between 1958 and 1961. Recent-
ly, Koprowski has described his experience in collabo-
ration with local scientists and wrote (8): »Another per-
son who appeared on the scene at this time was Drago
Iki}, head of the Immunology Institute of Zagreb in the
former Yugoslavia. Once decided, he carried out projects
meticulously. So it was when he decided to vaccinate
Croatia with our types 1 and 3 strains. In early spring of
1961, over 1,300,000 children in Croatia were given a
mixture of the two strains (9) and were controlled clini-
cally and serologically. No postvaccination polio was
seen and the serologic studies suggested that there were
at least 100,000 triple seronegatives in the vaccinated
population. The data showed a seroconversion of 91.5%
for type I and 93.5% for type 3 (10, 11). Later, Iki} pro-
duced attenuated poliovaccine locally using human di-
ploid cells and became well-known for his use of these
cells in vaccine production (11, 12).«
The area of poliomyelitis vaccine development was
very competitive. The second vaccine, developed in 1952
by Jonas Salk, was inactivated poliovirus vaccine (IPV)
based on a poliovirus grown in monkey kidney tissue
culture (Vero). Albert Sabin developed another live, oral
polio vaccine (OPV). Human trials of Sabin’s vaccine
began in 1957, and in 1958 it was selected, in competition
with the live vaccines of Koprowski, and in 1962 became
the only polio vaccine used worldwide. However, on very
rare occasions, the attenuated virus in OPV reverts into a
form that can paralyze. Recently, most industrialized
countries have switched to IPV, which cannot revert,
either as the sole vaccine against poliomyelitis or in com-
bination with oral polio vaccine.
Preparation of vaccines for other viral diseases at the
Institute of Immunology soon followed, including measles,
mumps, rubella (German measles), and rabies. Vaccine
development is a long process, with the time from early
research to licensure steadily increasing. At one time the
process took about ten years; now it takes closer to fifteen
to twenty years. The process begins with fundamental
research in universities or biotech firms who have an
idea. However, to take things further, there must be a
vaccine manufacturer, a regulatory authority ready to
give permission for the use of vaccine (licensing), and
public health authorities that will recommend and foster
vaccination. In 1963, when he started with development
of Edmonston-Zagreb measles vaccine strain, Drago Iki}
had it all. The original seed virus was obtained from
Musser laboratory as the Edmonston-Musser strain (Re-
search and Development Laboratories, Philips&Roxane
Inc., USA) with a history of 24 human kidney, 28 human
amnion tissue culture passages, 22 embryonated egg pass-
ages and 15 canine kidney cell culture passages. Drago
Iki} initiated subsequent passages in human diploid cell
culture WI-38 including three plaquings (in the 9th,
11th and 13th passages); in each, large plaques were
selected. The vaccine strain obtained at the end of this
procedure represented a homogenous, genetically stable
population of virus particles originating from one plaque.
In 1967, passage no. 22 on human diploid cells was
selected as master seed of Edmonston-Zagreb strain (13).
From 1984 the working seed lots have been produced in
homologous cell substrate, MRC-5 cells. Several studies
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have compared the effect of Edmonston-Zagreb and other
globally exploited measles vaccine strain by subcuta-
neous injection at the same dose and age, and found that
Edmonston-Zagreb vaccine gave superior seroconver-
sion rates.
The era of discovery continued with adaptation of
rubella virus RA 27/3 to HDCS. One feature of the
human diploid fibroblast vaccine that differed from the
others was the adaptation of the strain to growth at 30°C.
The idea behind this was to rapidly induce attenuation, on
the basis of previous experience with attenuated poliovirus
strains, following the work of others that showed that
replication at low temperatures selected against virulence.
By the 25th passage in a human diploid cell strain, RA
27/3 clearly became attenuated for humans. All the live
attenuated vaccines except RA 27/3, the human diploid
cell vaccine, were licensed in 1969 and 1970 in the United
States. At the same time, due to Drago Iki} and his
collaborators at the Institute of Immunology, RA 27/3
HDCS was licensed in Europe (former Yugoslavia,
France). The reason for this difference is of historical
interest (14). At the time, there was a prejudice in the
American regulatory agency against a human cell strain
on the grounds that it might contain some hypothetical
contaminating agent. Irrationally, primary cultures from
animals were thought to be preferable. But, over the years,
human diploid cell strains have become the reference




By the beginning of the twentieth century micro-
biology went through a phase of rapid proliferation and
specialization. Productive research was no longer con-
fined to France, Germany and Britain; first-rate labo-
ratories appeared in the United States, Japan, Russia,
Chile, Hungary and many developing countries includ-
ing former Yugoslavia. As a discipline, microbiology
encouraged international collaboration not only through
individual efforts but also through scientific societies.
The scientific societies concentrated considerable groups
of scientists, performed experiments and investigations
impossible to individual effort, encouraged individual
scientists and gave them both opportunity and leisure for
scientific work. They became centers of scientific in-
formation, published scientific books and periodicals,
propagated periodically scientific discoveries, and thus
co-ordinated the scientific efforts of various progressive
European countries.
The most prominent society was established as the
International Society for Microbiology (ISM) in 1927 at
the Pasteur Institute of Paris (the Belgian Nobel Lau-
reate Jules Bordet was elected as the first president).
During its long existence, the association has undergone
four name changes and eight major reorganizations. Fi-
nally in 1980 it grew in to the International Union of
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Figure 3. The participants of the 3rd International meeting of biological standardization hosted by Drago Iki} (third on the right in the first row) in
1957 in Opatija under the auspices of ISM.
Microbiological Societies (IUMS), an international non-
-governmental organization which supports the study of
microbiological sciences worldwide. It maintains contact
with other international organizations such as the UN,
UNESCO, WHO and the International Union of Bio-
logical Science (IUBS).
Under the auspices of ISM, Drago Iki} hosted in
1957, 1959, and 1960 three symposia in Opatija on biolo-
gical standardization, immunology and biological stan-
dardization, respectively (Figure 3). The meetings them-
selves brought together scientists of differing training,
occupation, and concerns, thereby expanding the views
and enhancing the productivity of researchers. Presen-
tations at meetings provide a means for scientists to learn
of the most recent discoveries, to gain an overview of the
field and to put their own work in a broader scientific
perspective. Drago Iki} had valuable presentations at the
meetings and was the editor of the proceedings. The
proceedings have done much to stimulate cooperation in
research, helping scientists and scientific societies to
keep in touch with each other.
The international character placed an additional duty
on the ISM standardization. The meeting in 1960 was
critical in forming a consensus on the core conceptual
tools among researchers working on biological standar-
dization, i.e. the standardization of drugs or biological
products that cannot be chemically analyzed by studying
their pharmacologic action on animals. This internatio-
nal meeting was organized to reach an agreement on a
common nomenclature and principles. Drago Iki}’s pre-
sentation on biological standards encompassed establish-
ment, criteria, stability, present state, requirements, dif-
ficulties, improvements, and proposals. He concluded
that in the elaboration of concrete proposals for the
promotion of biological standardization, the following
interests should be borne in mind: promotion of vaccine
production process, final vaccine control, development
of scientific work in the field of vaccines and interest of
the vaccinated population (15).
FOUNDATION OF WHO COLLABORATING
LABORATORY/CENTRE AT THE
INSTITUTE OF IMMUNOLOGY, ZAGREB
International health organizations traditionally attempt
to standardize procedures for medical microbiological
products. The first biological standard in the world, a
diphtheria antitoxin serum reference standard, was pre-
pared by Paul Ehrlich in 1897. A whole range of modern
remedies (antitoxins, hormones, vitamins, and certain
drugs) required that their strength be biologically mea-
sured against a standard preparation.
WHO has played a key role for over 50 years in
establishing the WHO Biological Reference Materials
necessary to standardize biological materials, as well as
in developing WHO guidelines and recommendations
on the production and control of biological products and
technologies. These norms and standards, based on scien-
tific consensus achieved through international consul-
tations, assist WHO Member States in ensuring the qua-
lity and safety of biological medicines and related in vitro
biological diagnostic tests worldwide. The Organization
accomplishes this work through its biological program-
me, the WHO Collaborating Centers, and the WHO
Expert Committee on Biological Standardization (ECBS).
This also involves close collaboration with the inter-
national scientific and professional communities, regio-
nal and national regulatory authorities, manufacturers
and expert laboratories worldwide.
By definition (16) »WHO collaborating centre forms
part of an inter-institutional collaborative network set up
by WHO in support of its programme at the country,
intercountry, regional, interregional and global levels. In
line with the present WHO policy and strategy of tech-
nical cooperation, a WHO collaborating centre must
also participate in the strengthening of country resour-
ces, in terms of information, services, research and train-
ing, in support of national health development….An
institution is designated initially for a term of four years;
the designation may be renewed…«
Between 1971 and 1997, two WHO Collaborating
Centers were active at the Institute of Immunology
(Table 1.):
TABLE 1
WHO Collaborating Centers in Institute of Immunology.
Period Title
1971–1997 Biological standardization: Research and referen-
ce services (Drago Iki}, Head and Principal Inve-
stigator) (cont. as WHO Collaborating Center for
Research and Reference Services for Immunobio-
logical Biological products, dr. Ivanka ^ana|ija,
Principal Investigator)
1973–1995 Reference Cenere for References and Research on
Bacterial Vaccines and Immunization programmes
(Drago Iki}, Head and Principal Investigator)
Reference materials are required to standardize po-
tency, purity, and identity measurements for complex
biological materials. For more than two decades Bio-
logical Reference Materials from the Institute of Immu-
nology provided a global standard against which experi-
mental values were compared and expressed, allowing
direct comparisons between products and measurements
across different methodologies and assays in use. The
experts from the Institute of Immunology served on the
Panel for the Biological Standardization of the WHO
from 1957 to 1982. Also, many of them have been as-
signed as WHO consultants. Headed by Drago Iki}, the
Institute organized WHO Interregional Courses for Bio-
logical Standardization in 1967, 1968, 1973 and 1976 to
support scientific exchange between developed and less-
-developed countries.
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VACCINE PREVENTABLE DISEASES,
IMMUNIZATIONS AND YEAR OF FIRST
LICENSURE 1961-2011
Finally, approval of a vaccine by national regulatory
authority for use in the practice based on the results of
randomized clinical trials of the vaccine’s protective ef-
ficacy is ultimate goal for vaccine inventor and scientist.
During his active work in vaccine development, manu-
facture and biological standardization, Drago Iki} and
the Institute of Immunology achieved substantial num-
ber of licensures. Understanding has been enhanced of
diseases now prevented by vaccines, many new vaccines
have been introduced and the occurrence of most of
these diseases has been dramatically reduced. Moreover,
due to close scientific ties with international community,
Croatian public health was competitive to the highly
developed countries. Table 2 illustrates the comparison
between licensure of selected vaccines in the U.S. and
Croatia. The year of first Croatian licensure does not
correlate necessarily to the introduction of vaccine in the
national immunization program.
NOT MENTIONED ABOVE
From this short text, many accomplishments of Drago
Iki} were omitted intentionally. Some very successful
ones are history now. Among them are: vaccination cam-
paign for smallpox eradication (an impressive amount of
30,000,000 doses of smallpox vaccine, Berna-Zagreb vac-
cine strain, were produced at the Institute of Immu-
nology between 1945 and 1969 for primary vaccination
and revaccination of children); design and production of
live influenza vaccine in 1962 and field trials in 1964 and
1968 when influenza appeared in Croatia in an epidemic
form; research and development of diverse combined
vaccines, and cost-effectiveness and cost-benefit analysis
of immunization programmes. In 1976 fractionated anti-
gens were developed from whooping cough component
(pertussis) of DTP vaccine but research on their potency,
stability and reactogenicity was interrupted after Drago
Iki} retirement.
At last, but not the least, since foundation of the
Institute of Immunology Drago Iki} promoted due to
experience with animal antitoxins, the production of
medicines derived from human blood and plasma. Nor-
mal human immunoglobulin prepared from pooled do-
nations and used for the prevention (or postexposure
prophylaxis) of susceptible contacts against common
pathogens was licensed in 1962. In 1967, following the
analysis of transfusiology development in Croatia and
the production of specific immunoglobulins obtained
from human plasma, especially of anti-tetanus and anti
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TABLE 2
Year of licensure of selected childhood vaccines.
Vaccine Year of first US licensure (17) Year of first Croatian licensure
(national producer)
Tetanus toxoid 1943 1954
Inactivated influenza 1945 Trivalent 1970 monovalent type A
1973 bivalent type A+B
Tetanus and diphtheria toxoids 1953 for children aged >7 yrs;
1970 for children aged <7 yrs
1955
Inactivated polio 1955 1959
Oral polio 1963 1961 Koprowski type I and III








1979 (rubella RA27/3 HDCS)
1967 (measles CEF);
1968 (measles HDCS);
1970 (rubella RA27/3 HDCS);
1972 (mumps);
1974 (measles–mumps–rubella combined)
Hepatitis B 1981 (plasma derived); 1986 (recombinant)
Haemophilus influenzae type b conjugate 1987 for children aged 18 mos; 1990 for infants
Live attenuated influenza 2003 1968
Meningococcal conjugate 2005 1978 (group A+C)
Rh0 (D) immunoglobulin, along with already present
cryoprecipitate, normal gamma globulin and albumin,
the research began of fractionation of human plasma.
Licensure of antilymphocyte globulin followed in 1972.
The production and clinical use of human leukocyte
interferon (IFN) is a domain where Drago Iki} has been
active from the very beginning. Clinical use of interferon
worldwide started in 1968. Since 1972, when human
leukocyte interferon was licensed in Croatia, until 1975
five hundred and forty patients with viral and malignant
diseases underwent interferon treatment. At the same
time mode of its action was studied, many scientific
papers were published and three international symposia
were organized. His interest in interferon is still vivid
and hopefully Drago Iki}’s research of these immune
regulation molecules will draw our attention for many
years from now.
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